First spet images of glutamate (nmda) receptor activation in vivo in cerebral ischaemia

Nuclear Medicine Communications

Volumn 18, Issue 2, 1997, Pages 149-158

  Owens, J ^a   Elliott, A T ^a   Wyper, D J ^b   Patterson, J ^b   Brown, D R P ^c   Teasdale, G M ^d   McCulloch, J ^d  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^b Southern General Hospital NHS Trust   (United Kingdom)

^c Leverndale Hospital   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIZOCILPINE; IODINE 123; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AGED; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0030902724     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199702000-00010     Document Type: Article

References (39)

1. Lipton SA, Rosenburg PA. Excitatory amino acids as a final common pathway for neurologic disorders. New Eng J Med 1994; 330: 613-622.
2. McCulloch J, Teasdale GM, Bullock R. Excitatory amino acid antagonists: Opportunities for the treatment of ischaemic brain damage in man. In: Meldrum BS, ed. Excitatory amino acid antagonists. Oxford: Blackwell Scientific, 1991: 287-326.
3. McCulloch J. Excitatory amino acid antagonists and their potential use for the treatment of ischaemic brain damage in man. Br J Clin Pharmacol 1992; 34: 106-114.
4. Kemp JA, Foster AC, Wong EHF. Non-competitive antagonists of excitatory amino acid receptors. TNS 1987; 10: 294-298.
5. Foster AC, Wong EHF. The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain. Br J Pharmacol 1987; 91: 403-409.
6. Jacobson W, Cottrell GA. Rapid visualisation of NMD A receptors in the brain: Characterisation of (+)-3-[125I]-iodo-MK-801 binding to thin sections of rat brain. J Neurosci Meth 1993; 46: 17-27.
7. Rajdev S, Reynolds IJ. Effects of monovalent and divalent cations on 3-(+)-iododizocilpine binding to the JV-methyl-D-aspartate receptor of rat brain membranes. J Neurochem 1992; 58: 1469-1476.
8. Ransom RW, Eng W, Burns HD et al. (+)-3-[123I]iodo-MK-801: Synthesis and characterisation of binding to the N-methyl-D-aspartate receptor complex. Life Sci 1990; 46: 1104-1110.
9. Wallace MC, Teasdale GM, McCulloch J. Autoradiographic analysis of 3H-MK-801 (dizocilpine): in-vivo uptake and in-vitro binding after focal cerebral ischaemia in the rat. J Neurosurg 1992; 76: 127-133.
10. McCulloch J, Wallace MC, Laurie D et al. Imaging activation in the NMD A receptor complex with 125I-iodo-MK-801. In: Kreiglstein J, Oberpichler-Schwenk H, eds. Pharmacology of cerebral ischaemia. Stuttgart: Wissen-schaftliche Verlagsgesellschaft mbH, 1992: 59-64.
11. Wilbur DS, Anderson KW, Stone WE, O'Brien HA. Radio-halogenation of non activated aromatic compounds via aryltrimethylsilyl intermediates. J Lab Comp Radiopharm 1982; 19: 1171-1188.
12. Wilson A A, Dannals RF, Ravert HT et al. 125-1 and 123-1 labelled iodobenzylbromide, a useful alkylating agent for radiolabelling biologically important molecules. J Lab Comp Radiopharm 1986; 23: 83-93.
13. Wilson AA, Dannals RF, Ravert HT et al. Synthesis and biological evaluation of [1251]-and [123I]-4-iododexeti-mide, a potent muscarinic receptor antagonist. J Med Chem 1989; 32: 1057-1062.
14. Seevers RH, Counsell RE. Radioiodination techniques for small organic molecules. Chem Rev 1982; 82: 575-590.
15. Coenen HH, Moerlein SM, Stocklin G. No carrier added radiohalogenation methods with heavy halogens. Radiochi-mica Acta 1983; 34: 47-68.
16. Verhoeff NPLG, Sokole EB, Stabin M et al. Dosimetry of iodine-123 iodobenzamide in healthy volunteers. Eur J Nucl Med 1993; 20: 747-752.
17. International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. New York: Pergamon Press, 1987.
18. Innis RB, Malinson RT, Al-Tikriti M et al. Amphetamine-stimulated dopamine release competes in vivo for 123I[IBZM] binding to the D2 receptor in non human primates. Synapse 1992; 10: 177-184.
19. McCulloch J. Excitotoxicity and its pharmacological modification in experimental focal ischaemia. Stroke 1992; 23: 1200-1201.
20. Vezzani A, Serafini R, Stasi MA et al. Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. J Pharmac Exp Ther 1989; 249: 278-283.
21. Hucker HB, Hutt JE, White SD et al. Disposition and metabolism of (+)-5-methyl-10, ll-dihydro-5Hdibenzo[a, d]-cyclohepten-5,10-imine in rats, dogs and monkeys. Drug Metab Disp 1983; 11: 54-58.
22. Ferarrese C, Guidotti E, Costa E et al. In-vivo study of NMDA-sensitive glutamate receptor by fluorothienylcy-cloexylpiperidine, a possible ligand for positron emission tomography. Neuropharmacology 1991; 30: 899-905.
23. Blin J, Yamagushi T, Crouzel C et al. PET studies of 18F-fluoroethyl-MK-801 in the baboon’s brain: A potential NMDA receptor complex radioligand. J Cereb Blood Flow Metab 1989; 9(suppl. 1): 13.
24. Weiland DM, Kilbourn MR, Yang DJ et al. NMDA receptor channels: Labeling of MK-801 with iodine-125 and fluorine-18. Appl Radiat Isot 1988; 39: 1219-1225.
25. Price GW, Ahier RG, Middlemiss DN et al. In-vivo labelling of the NMDA receptor channel complex by [3H]MK-801. Eur J Pharmacol 1988; 108: 279-282.
26. Gibson RE, Burns HD, Thorpe HH et al. In-vivo binding and autoradiographic imaging of (+)-3-[,25I]iodo. Nucl Med Biol 1992; 19: 319-326.
27. Porter RHP, Greenamyre JT. Inhibition of autoradiographic MK-801 binding by an endogenous factor. Neurosci Lett 1994; 169: 105-108.
28. Siesjo BK. Brain energy metabolism. Chichester: John Wiley, 1978: 304.
29. Tomlinson FH, Anderson RE, Meyer FB. Acidic foci in the penumbra of the New Zealand white rabbit. Stroke 1993; 24: 2030-2040.
30. Traynelis SF, Cull-Candy SG. Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons. Nature 1990; 345: 347-350.
31. Bowery NG, Wong EHF, Hudson AI. Quantitative autoradiography of [3H]-MK-801 binding sites in mamalian brain. Br J Pharmacol 1988; 93: 944-954.
32. Sakurai SY, Ca J-HJ, Penny JB, Young AB. Regional distribution and properties of [3H]MK-801 binding sites determined by quantitative autoradiography in the rat brain. Neuroscience 1991; 40: 533-543.
33. Procter AW, Wong EHF, Stratmann GC et al. Reduced glycine stimulation of [3H]MK-801 binding in Alzheimer’s disease. J Neurochem 1989; 53: 698-704.
34. Ulas J, Brunner LC, Geddes JW et al. N-Methyl-D-aspartate receptor complex in the hippocampus of elderly, normal individuals and those with Alzheimer’s disease. Neuroscience 1992, 49: 45-61.
35. Powers WJ, Grubb RL, Darriet D, Raichle ME. Cerebral blood flow and cerebral metabolic rate of oxygen requirements for cerebral function and viability in humans. J Cereb Blood Flow Metab 1985; 5: 600-608.
36. Jones SC, Greenberg JH, Dann R et al. Cerebral blood flow with continuous infusion of oxygen-15-labeled water. J Cereb Blood Flow Metab 1985; 5: 566-575.
37. Baron JC, Bousser MG, Comar D, Duquesnoy N. Crossed cerebellar diaschisis: A remote function depression secondary to supratentorial infarction in man. J Cereb Blood Flow Metab 1981; 1(suppl.): 500-501.
38. Muir KW, Grosset EXJ, Gamzu E, Lees KR. Pharmacological effects of the non-competitive NMDA antagonist CNS1102 in normal volunteers. Br J Clin Pharmacol 1994; 38: 33-38.
39. Albers GW, Alto P, Atkinson R et al. Safety, tolerability and pharmacokinetics of the N-methyl-D-aspartate antagonist dextromorphan in patients with an acute stroke. Neurology 1994; 44(suppl. 2): 577.